Predictive value ofex vivobiodynamic imaging in determining response to chemotherapy in dogs with spontaneous non-Hodgkin's lymphomas: a preliminary study.
Biodynamic imaging (BDI) is a novel phenotypic cancer profiling technology which optically characterizes changes in subcellular motion within living tumor tissue samples in response toex vivotreatment with cancer chemotherapy drugs. The purpose of this preliminary study was to assess the ability ofex vivoBDI to predictin vivoclinical response to chemotherapy in ten dogs with naturally-occurring non-Hodgkin's lymphomas. Pre-treatment tumor biopsy samples were obtained from all dogs and treatedex vivowith doxorubicin (10μM). BDI measured six dynamic biomarkers of subcellular motion from all biopsy samples at baseline and at regular intervals for 9 h following drug application. All dogs subsequently received doxorubicin to treat their lymphomas. Best overall response to and progression-free survival time following chemotherapy were recorded for all dogs. Receiver operating characteristic (ROC) curves were used to determine accuracy and identify possible cut-off values for the BDI-measured biomarkers which could accurately predict those dogs' cancers that would and would not respond to doxorubicin chemotherapy. One biomarker (designated 'MEM') showed 100% discriminative capability for predicting clinical response to doxorubicin (area under the ROC curve = 1.00, 95% CI 0.692-1.000), while other biomarkers also showed promising predictive capability. These preliminary findings suggest thatex vivoBDI can accurately predict treatment outcome following doxorubicin chemotherapy in a spontaneous animal cancer model, and is worthy of further investigation as a technology for personalized cancer medicine.
Department of Veterinary Clinical Sciences, Purdue University College of Veterinary Medicine, Purdue University, 625 Harrison Street, West Lafayette, IN 47907-2026, USA.
M R
MR
Custead
Department of Physics and Astronomy, Purdue University Department of Physics and Astronomy, Purdue University, 525 Northwestern Avenue, West Lafayette, IN 47907-2036, USA.
R
R
An
Department of Basic Medical Sciences, Purdue University College of Veterinary Medicine, Purdue University, 625 Harrison Street, West Lafayette, IN 47907-2026, USA.|Purdue University Center for Cancer Research, Purdue University College of Veterinary Medicine, Purdue University, 625 Harrison Street, West Lafayette, IN 47907-2026, USA.
J J
JJ
Turek
Department of Comparative Pathobiology, Purdue University College of Veterinary Medicine, Purdue University, 625 Harrison Street, West Lafayette, IN 47907-2026, USA.
G E
GE
Moore
Department of Physics and Astronomy, Purdue University Department of Physics and Astronomy, Purdue University, 525 Northwestern Avenue, West Lafayette, IN 47907-2036, USA.|Purdue University Center for Cancer Research, Purdue University College of Veterinary Medicine, Purdue University, 625 Harrison Street, West Lafayette, IN 47907-2026, USA.
D D
DD
Nolte
Department of Veterinary Clinical Sciences, Purdue University College of Veterinary Medicine, Purdue University, 625 Harrison Street, West Lafayette, IN 47907-2026, USA.|Purdue University Center for Cancer Research, Purdue University College of Veterinary Medicine, Purdue University, 625 Harrison Street, West Lafayette, IN 47907-2026, USA.
M O
MO
Childress
animal model; cancer; personalized medicine; phenotypic profiling